---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-094041"
form_type: "8-K"
ticker: "GANX"
cik: "0001819411"
company_name: "Gain Therapeutics, Inc."
filed_at: "2026-08-11T20:05:23+00:00"
generated_at: "2026-08-11T20:07:33.585408+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Gain Therapeutics Q2 2026 net loss $0.11/share; FDA clears IND for rexaceract Phase 2

## Summary
- Net loss per share $0.11 (basic/diluted) vs $0.19 in Q2 2025; cash $13.1M at June 30, 2026.
- FDA accepted IND for rexaceract (GT-02287); Phase 2 in Parkinson's expected to start Q3 2026.
- R&D expenses fell to $2.1M from $2.8M; G&A rose to $2.5M from $2.3M year-over-year.
- Phase 1b final results due Q4 2026; 14 of 16 extension participants completed Day 270.
- Promoted Joanne Taylor to CSO and Terenzio Ignoni to COO; GT-04686 indication expected by year end.

## SEC filing metadata
- accession: 0001104659-26-094041
- form_type: 8-K
- ticker: GANX
- cik: 0001819411
- company_name: Gain Therapeutics, Inc.
- filed_at: 2026-08-11T20:05:23+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819411/000110465926094041/0001104659-26-094041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819411/000110465926094041/ganx-20260811x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-094041
- JSON: https://secwatch.observer/filing/0001104659-26-094041.json
- Plain text: https://secwatch.observer/filing/0001104659-26-094041.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.